Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etokimab in adult peanut allergy
NCT02920021Phase 2Completed
- Sponsor
- AnaptysBio, Inc.
- Start
- Jan 2017
- Primary completion
- Mar 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in peanut allergy comparing Etokimab with Placebo (2 arms). Primary endpoints: Number of Participants With Treatment-emergent Adverse Events at 45 days and Change From Baseline in Cumulative Tolerated Peanut Dose During Oral Food Challenge at Day 14. Started Jan 2017; status: completed.
02
Drugs
etokimab
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT02920021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02920021.